Malignant cell transformation commonly results in the deregulation of thousands of cellular genes, an observation that suggests a complex biological process and an inherently challenging scenario for the development of effective cancer interventions. To better define the genes/pathways essential to regulating the malignant phenotype, we recently described a novel strategy based on the cooperative nature of carcinogenesis that focuses on genes synergistically deregulated in response to cooperating oncogenic mutations. These so-called 'cooperation response genes' (CRGs) are highly enriched for genes critical for the cancer phenotype, thereby suggesting their causal role in the malignant state. Here, we show that CRGs have an essential role in drugmediated anticancer activity and that anticancer agents can be identified through their ability to antagonize the CRG expression profile. These findings provide proof-of-concept for the use of the CRG signature as a novel means of drug discovery with relevance to underlying anticancer drug mechanisms.
INTRODUCTION
Differential gene expression associated with malignant cell transformation aids development of molecular diagnostic and prognostic applications for the cancer clinic. For example, genomic gene expression signatures can distinguish between tumors of different tissue of origin, 1 and segregate various cancer sub-types with distinct clinical features, as, for example, in B-cell lymphoma, 2 breast cancer 3 or lung cancer. 4 Further, genomicsbased tumor sub-typing, in several instances, has improved disease outcome predictions previously merely based on histological classification, [5] [6] [7] [8] and gene expression signatures can be used as a surrogate to identify signaling pathway activity associated with specific cancer gene mutations. 9 Notably, cancer gene expression profiling can also help to match drugs with drugsensitive cancers, [6] [7] 10 and mimetic drugs can be identified based on genomic comparison of gene signatures following treatment with a variety of compounds. [11] [12] [13] [14] [15] [16] [17] [18] Owing to the high complexity of differential gene expression patterns associated with cancer, however, the causal relevance of available expression signatures for the cancer phenotype remains largely unknown, thus confining their application to correlative approaches. Utilization of gene expression signatures for discovery of novel intervention strategies and mechanistic analysis has thus remained limited.
Key features of the cancer cell phenotype, such as uncontrolled proliferation, cell motility and invasiveness, only emerge as a result of the interplay between multiple cooperating oncogenic mutations. [19] [20] [21] [22] [23] [24] [25] [26] [27] This suggested that oncogenic mutations cooperate through converging mechanisms that involve synergistic regulation of key downstream mediators. Recent work from our laboratory directly supports this idea, as we have shown that multiple oncogenic mutations cooperate in malignant cell transformation through synergistic deregulation of a relatively small group of approximately 100 downstream genes, termed cooperation response genes (CRGs). These genes were subselected from the list of genes differentially expressed between young adult mouse colon (YAMC) cells and their malignant derivatives transformed with a pair of cooperating oncogenic mutations, that is, mutant p53 and activated Ras. Synergistic regulation of CRGs was detected by comparing gene expression levels in cells harboring either mutant p53 or activated Ras, or both oncogenic mutations combined. Remarkably, we found that reversing the deregulation of individual CRGs in malignant cells via genetic perturbation induced strong inhibition of tumor growth at a frequency of approximately 50%. In contrast, equivalent perturbations of differentially expressed non-CRGs yielded tumor inhibition at a frequency near 5%. CRGs thus effectively pinpoint a multitude of drivers of malignant cell transformation downstream of oncogenic mutations among the complex patterns of differential gene expression arising as a consequence of the cancer phenotype. 28 The causal role of CRGs in malignant transformation indicates that modulation of CRG expression is functionally relevant to the cancer phenotype. We thus reasoned that reversal of CRG expression in response to pharmacological agents may be a powerful indicator of anticancer activity. In addition, CRGs are implicated in the control of virtually all features of cancer cells, such as proliferation, survival, invasiveness and metabolism, suggesting that cooperating oncogenic mutations drive malignant cell transformation by simultaneously enabling multiple cancer cell traits through modulation of CRG expression. 28 Accordingly, modulation of the CRG expression signature by anticancer agents should provide insight into underlying mechanisms of drug action.
RESULTS

Compounds antagonizing the CRG signature
Reprogramming expression of individual CRGs in cancer cells to levels found in normal parental cells via genetic perturbation inhibits tumor formation with high efficacy. 28 We thus hypothesized that pharmacological agents capable of antagonizing the CRG signature also may inhibit tumor growth, presumably through altering CRG expression. To identify compounds with such potential, we interrogated the Connectivity Map (CMap) database 14, 29 searching for compounds that reversed the CRG expression signature, that is, suppressed upregulated CRGs and activated downregulated CRGs. Among the compounds that maximally antagonized CRG expression, we found that 9 out of the top 20 represented histone deacetylase inhibitors (HDIs) (Figure 1a , Supplementary Table 1) , compounds with known anticancer effects. 30 HDI thus emerged as an example to test our hypothesis that CRGs can be used as a causally relevant multi-dimensional tool for identification of anticancer agents together with underlying mechanisms of action. Given the strong enrichment for HDI as antagonizing the CRG signature in multiple human cancer cell lines and the strong negative CSs (see also below), we chose to focus on HDI for proof-ofprinciple experiments testing a causal relationship between pharmacological modulation of the CRG signature and the biological outcome of such modulation.
Notably, HDIs demonstrated an overall tendency to antagonize rather than enhance the CRG expression signature (Figure 1b) . Nevertheless, given that HDIs affect the expression of numerous genes, we next sought to estimate the significance and specificity of our findings. To this end, we challenged the CMap with 1000 randomly generated signatures, each comprising 76 genes as the CRG signature, and found that none of these simulated signatures could demonstrate the overall level of antagonism as the CRG signature (Figure 1c ; Po0.001). Next, we determined whether CMap identification of HDI instances, negatively connected to the CRG signature, was due to HDI being general antagonists of gene expression signatures arising from perturbation of most any pathway. To explore this possibility, we used CMap2, which contains gene expression signatures arising from 5842 non-HDI chemical perturbations and hence is reflective of many pathway perturbations. The 24 most upregulated and 52 most downregulated genes from each CMap2 non-HDI instance were selected and used to query CMap1. The frequency of negative connectivity of the same magnitude as the CRG signature to HDIs by any of the 5842 signatures was very low (o0.017%; Figure 1d ). Overall, these observations strongly suggested a very specific and non-random relationship between the CRGs and the influence of HDIs on them.
A variety of natural and synthetic compounds function as HDI 30 and induce cell cycle arrest, differentiation and apoptosis selectively in murine and human cancer cell lines in vitro and inhibit tumor formation in vivo. [31] [32] [33] [34] [35] These drugs inhibit the function of histone deacetylases, which remove acetyl groups from lysine residues on histone tails, thus inducing chromatin condensation, 36 associated with heterochromatin formation and transcriptional silencing. 37, 38 HDI are currently under clinical evaluation as single agents [39] [40] [41] [42] [43] [44] [45] or in combination with existing chemotherapeutic agents. [46] [47] [48] [49] Exposure of a variety of human cancer cells, such as PC3 prostate carcinoma cells, MCF-7 breast carcinoma cells or HL-60 acute myeloid leukemia cells, to the CMap-identified HDI valproic acid (VA), 14 caused alterations in CRG expression levels, resulting in an inverted pattern as compared with the CRG expression signature (Supplementary Figure 1) . The cell lines indicated carry Ras and loss-of-function p53 mutations that can cooperatively control CRG expression, in the form of loss of p53 and mutation of N-Ras in HL-60 cells, or mutations in key components of the Ras and p53 pathways, such as loss of p53 and phosphatase and tensin homolog deleted on chromosome 10 (PTEN) in PC3 cells, and mutation in PI3-kinase and loss of p16/p14 in MCF-7 cells. 50 HDI reverse CRG signature in mp53/Ras cells As CRGs are critical for the malignant state, our finding that HDI antagonize the CRG signature in multiple human cancer cell contexts suggested that this class of compounds, at least in part, may act through resetting CRG expression. In order to test this prediction, we first examined the sensitivity to HDI of YAMC cells 51 transformed with activated Ras and mutant p53 (mp53/Ras cells), where CRG expression is known to be essential for tumor formation. 28 The relevance of CRG modulation for the biological effects of HDI on cancer cells was tested based on the notion that HDI can inhibit tumor formation in vivo, 34,52-53 a context where the role of CRGs is well defined. Either of the HDI, VA and sodium butyrate (NB), a naturally occurring HDI structurally related to VA, strongly inhibited the ability of treated cells to form tumors when grafted onto immune-compromised mice ( Figure 2a ). In particular, HDI treatment reduced the frequency of tumor take after implantation by B75%, that is, the number of tumors growing larger than the 0.1 cm 3 cell transplant in 4 weeks ( Table 1) . For these experiments, cells were exposed to a single dose of either VA or NB for 72 h in tissue culture, whereas further functional testing was carried out in absence of drug. 53 This procedure allowed for monitoring of CRG expression following HDI pretreatment, before cell transplantation into animals. Under these conditions, HDI treatment induced a cytostatic effect without apoptosis in cell culture (Supplementary Figure 2, Figure 3a ). HDI treatment apparently did not act by targeting the initiating oncogenes, as mp53 and Ras protein levels virtually remained unaltered (Supplementary Figure 4) . Similarly, the GTP-binding activity of mutant Ras also remained unaffected by either mutant p53 or VA and NB (Supplementary Figure 5) , consistent with the idea that modulation of CRG expression acts downstream of oncogenic mutations.
As CRGs are critical to tumor formation capacity of transformed cells, we next examined the CRG expression response in mp53/Ras cells treated with VA or NB, as compared with untreated controls, using TaqMan low-density arrays with probes to 76 of 95 CRGs, based on probe set availability. Notably, the expression of 39 (B50%) of the 76 CRGs tested responded to HDI exposure, affecting CRG expression in a demonstrably antagonistic manner (Figures 2b and c, Supplementary Figures 6 and 7 ; Po0.05, unadjusted t-test). The responses to both VA and NB were highly similar, with 30 out of 39 of the responding genes in common between the two drugs. Moreover, genes with increased expression in response to HDI also showed an increase in histone acetylation at their promoters, whereas genes whose expression was unaffected show virtually no alteration in promoter acetylation on drug treatment (Supplementary Figure 8 Table 1 , Supplementary Figure 11 ), thus demonstrating a causal role for each of these genes in tumor suppression by HDI. Notably, induction of Dapk1, Notch3, Noxa or Perp expression by HDI becomes evident only between 48 and 72 h following drug exposure, suggesting that relatively late alterations in gene expression mounted in response to HDI are essential to generating HDI sensitivity of tumor formation capacity (Supplementary Figure 12) . CRG perturbations had no significant effect, however, on HDI-mediated inhibition of cell accumulation in vitro (Supplementary Figure 3B) , suggesting that CRGs are integral to antitumor effects of HDI, but not necessarily antiproliferative effects in vitro.
The roles of Dapk1, Notch3, Noxa, Perp or Fas, in HDI-mediated tumor inhibition appear distinct. Induction of Dapk1 expression by HDI appears essential and specific for establishing tumor sensitivity toward HDI. ShRNA-mediated suppression of Dapk1 mRNA expression completely abrogated HDI-mediated tumor inhibition, that is, generates HDI resistance, whereas having no effect on tumor growth in the absence of HDI. Notch3, Noxa and Perp have an intermediate role, with each of the respective knock down cell populations exhibiting reduced NB sensitivity, as compared with genetically unperturbed controls. In contrast, Fas and HDI suppress tumor formation through independent mechanisms. Both HDItreated and -untreated cells formed significantly larger tumors following knock down of Fas expression, and conversely HDI sensitivity of Fas-perturbed cells was similar to that of unperturbed cells (Figure 3a) . CRG induction by HDI thus contributes to HDI antitumor activity through multiple mechanisms.
Gene knock down appears to be specific for the targeted CRGs and affects cell regulation downstream of oncogenic mutations.
Multiple independent shRNAs for each of the genes consistently led to increased tumor growth (Supplementary Figure 11 Figure 3C) . Notably, we find a similar scenario, following exposure of murine mp53/Ras cells to the second generation HDI, suberoylanilide hydroxamic acid. As expected, suberoylanilide hydroxamic acid inhibited the proliferation of mp53/Ras cells in vitro. However, neither CRG response, nor antitumor effects were observed following suberoylanilide hydroxamic acid treatment of these cells (Supplementary Figure 14) . Our observations thus suggest that antagonistic regulation of CRG expression by pharmacological agents can serve as an indicator for antitumor effects. As demonstrated below, regulation of CRG expression has a causal role in HDI antitumor activity in human colon cancer cells as well as in transformed murine colon cells. Overall measurement of the CRG response to HDI in SW480 cells with available probes to 64 of the 95 CRGs revealed altered expression of 60% of the CRG signature following exposure to either VA or NB (Figure 5a,  Supplementary Table 2) , with 21 genes responding similarly to both VA and NB, and 16 of these genes showing differential expression at a statistically significant level (Figure 5b , Po0.05, t-test). Among the nine genes responsive to NB and VA in SW480 and mp53/Ras cells were DAPK1, NOTCH3 and PERP. As a result of the important role of Dapk1 in HDI effects on murine colon cells, and strong induction by both VA and NB in SW480 cells, we tested the role of DAPK1 in the antitumor activity of HDI on human cells. Similar to mp53/Ras cells, DAPK1 knock down (Figures 5c and d Supplementary Figure 15 -indicating two independent shRNA constructs) renders tumor formation capacity of SW480 cells virtually resistant to NB, whereas genetically unperturbed control cells show a significant reduction in tumor growth in response to NB (Figure 5e; Supplementary Figure 15 ). As shown above, the modulation of the HDI response by CRG perturbation is specific to HDI antitumor activity, as the HDI ability to inhibit cell proliferation in tissue culture was not affected by knock down of Dapk (Supplementary Figure 3D) . The effects of HDI and DAPK1 shRNA are not mediated by altered expression of the initiating oncogenic mutant proteins. Levels of oncogenic Ras proteins were virtually unaffected by either HDI treatment or DAPK1 knock down in SW480 cells (Supplementary Figure 16) . Furthermore, SW480 cells are null for wild-type p53. 57 HDI sensitivity at the level of tumorigenicity thus depends on DAPK1 expression in human as well as in murine cancer cells. Taken together, we conclude that modulation of CRG expression has a causal role in the antitumor effects of HDI in both murine and human cancer cells.
DISCUSSION
Here, we provide proof-of-concept that a gene expression signature comprising genes essential to the cancer phenotype has utility for discovery of anticancer agents and their underlying mechanisms of action. Previously, we have shown that drivers of the cancer phenotype downstream of oncogenic mutations can be identified based on their synergistic deregulation by cooperating oncogenic mutations. We now demonstrate that these socalled 'CRGs' have an essential role in drug-mediated anticancer activity and that anticancer agents can be identified through their ability to reverse the CRG expression profile. Notably, reversal of CRG expression by anticancer agents appears integral to underlying drug mechanism. Our data thus reveal the CRG expression profile as a powerful probe to identify anticancer agents acting downstream of multiple cancer gene mutations.
Specifically, we show that the CRG signature is antagonized by HDIs in a cancer cell-specific manner, and that such reversal of CRG expression is essential for HDI anticancer activity. Treatment of mp53/Ras cells with VA or NB, two carboxylic acid HDI, partially reversed expression of 50% of the 76 CRGs tested. Among the HDI-regulated CRGs are a number of genes that are repressed in transformed cells and reactivated by HDI. These include Dapk1, Fas, Notch3, Noxa and Perp. Notably, Dapk1, Notch3, Noxa or Perp each have causal roles in the antitumor activity of HDI, as shRNAmediated knock down of any of these four genes decreases cancer cell sensitivity to HDI. Conversely, Fas suppresses tumor growth independent of HDI sensitivity, a feature that previously remained undetected. 35 Upregulation of individual CRGs by HDI thus contributes to HDI antitumor activity involving multiple paths. We thus demonstrate that reversal of CRG expression by pharmacological agents is integral to the underlying anticancer drug mechanism and that the mechanism involved may be multidimensional in nature.
In addition to providing insight into mechanisms underlying antitumor activity of pharmacological agents, our findings also identify a means by which cancer cells may acquire resistance to previously effective compounds. 58 Inhibition of HDI-mediated induction of the five CRGs mentioned above significantly restored tumor formation capacity of transformed cells. This indicates that tumors can evade the effects of HDI through multiple paths, with modulation of gene regulation as a general theme. Such a mechanism of mounting drug resistance may be effective against a series of pharmacologic agents. In fact, such acquired resistance to therapeutic agents through multiple routes has also been recently observed in an in vitro model of non-small cell lung cancer. 59 Conversely, this type of resistance may be overcome by drug combinations, composed of agents that perhaps, as discussed below, each modulate diverse sub-sets of CRGs. Alternatively, drug resistance may be circumvented by compounds that boost expression of tumor inhibitory CRGs that act independent of drug resistance, as, for example, shown here for Fas expression.
Our observation that reversion of the CRG signature is essential for the tumor inhibitory activity of anticancer compounds has important practical implications. First, the CRG signature provides a new means for anticancer drug discovery based on insights relating to drug mechanism. We thus anticipate that the CRG signature will allow functional classification of compounds with anticancer activity based on the distinct CRG expression patterns they elicit. In this context, it is also worth noting that the CRG signature effectively identified tumor inhibitory compounds across gene expression profiles from drug-treated breast, prostate and myeloid cancer cells. Preliminary observations in our laboratory show antagonism of the CRG signature by other known anticancer compounds, with the relevance of such change in CRG expression currently under investigation. CRG expression patterns thus may serve as an indicator for antitumor activity, as a surrogate for tumor cell behavior in vivo, thereby facilitating identification of potential anticancer compounds, perhaps with relevance to multiple types of human cancer. Second, we envisage that the responsiveness of the CRG signature to pharmacologic agents can also function as a diagnostic indicator of cancer cell sensitivity to such agents, wherever CRGs contribute to the cancer phenotype.
CRGs have emerged as a highly valuable resource for understanding mechanisms essential to both the cancer phenotype and anticancer drug activity. CRG selection specifically detects genes that are regulated by multiple oncogenic mutations. Moreover, as CRGs are essential to the cancer phenotype, they represent key elements in the molecular architecture underlying malignant transformation. CRGs thus provide fundamental insight into the mechanisms generating and maintaining the malignant state and indicate associated cancer cell vulnerabilities as points for intervention downstream of oncogenic mutations. Moreover, as shown here, reversal of the CRG expression signature by pharmacological agents pinpoints key components in underlying drug mechanism. In addition, the considerable number of CRGs offers access to developing cancer interventions in a multidimensional manner providing rationale for combinations of molecularly targeted drugs. These are exciting prospects for cancer intervention strategies with high cancer selectivity and with broader application.
MATERIALS AND METHODS
Interrogation of the CMap database
To facilitate cross-species queries, a local version of the CMap database was downloaded and remapped to gene symbols. 14 When multiple Affymetrix IDs mapped to a single gene symbol, the median fold change for that gene was utilized. This local gene symbol-based version of the CMap performed similarly to the Affymetrix ID-based version originally described.
The query signature consisted of 24 upregulated CRGs and 52 downregulated CRGs for which gene symbol annotation was present in the CMap data set. This 76-gene subset of the CRG signature was used to interrogate the CMap database according to the connectivity score (CS) metric, previously described.
14 The Kolmogorov-Smirnov-based gene set enrichment analysis algorithm 29 was used to obtain enrichment scores for both upregulated (ES up ) and downregulated (ES down ) CRGs for each CMap drug treatment instance. The values of ES up and ES down were combined to generate a CMap CS as described. Drugs that mimic the CRG signature attain a positive CS whereas drugs that antagonize the CRG signature attain a negative CS.
To test the randomness of results, 1000 random gene 76-gene signatures consisting of the same proportion of upregulated and downregulated genes as the CRG signature were generated. Each random signature was used to interrogate the CMap database. The non-normalized CSs for the relevant HDI instances were summed together and multiplied by À 1 to make the value positive (negative summed non-normalized CS; À sum(nCS)). Positively connected instances and non-connected instances were assigned a value of zero. The P-value indicates the number of random comparisons achieving as extreme a summed score or greater.
To determine specificity, we obtained fold changes for all genes resulting from 5842 non-HDI chemical perturbations in CMap2. From these data, 5842 76-gene signatures were generated according to fold change, using the 24 most upregulated and 52 most downregulated genes. Each 76-gene signature was used to interrogate CMap1 and the À sum(nCS) was computed as above.
Cell culture, retroviral infections and tumor formation assays
The YAMC cell system 51 and transformation of these cells by both p53
175H
and HRas V12 (mp53/Ras) are described elsewhere. 27, 28 YAMC and mp53/Ras cells were cultured for 2 days at 39 1C in RPMI with 10% fetal bovine serum on collagen IV-coated dishes. Cells were then re-plated on collagen IVcoated dishes into the same medium containing either 2.5 mM NB, 2.5 mM VA, 5 or 10 mM suberoylanilide hydroxamic acid or no drug for 72 h at a density of 4.58 Â 10 5 cells per 15-cm dish at 39 1C. SW480, SW620 and DLD-1 cells were grown at 37 1C in Dulbecco's modified Eagle's medium with 10% fetal bovine serum and antibiotics. For HDI treatment of human colon cancer cells, cells were plated into medium containing either 2.5 mM NB, 2.5 mM VA or no drug for 72 h at a density of 1.37 Â 10 6 cells per 15-cm dish. For all cell types, following HDI treatment, cells were harvested for RNA isolation, or used for tumor formation studies as described below. Polyclonal cell populations stably expressing individual shRNA molecules targeting each of the tested CRGs were generated as previously described. 28 shRNA target sequences are listed in Supplementary Table 3 . For each upregulated gene, we identified 2-3 independent shRNA target sequences yielding at least 50% reduction in gene expression with the goal to guard against off-target effects (Supplementary Figure 10) . The specificity of Noxa and Perp knock down was independently confirmed by expression of complementary DNA for either of these genes, rendered shRNA resistant by introduction of appropriate silent mutations. Gene expression was achieved using the pBabe-hygro retroviral vector to introduce either complementary DNA into appropriate mp53/Ras cells harboring Noxa or Perp shRNA using the methods described above.
For tumor formation studies, cells were treated with HDI, then trypsinized, counted and injected subcutaneously into the flanks of CD-1 nude mice at a multiplicity of 5 Â 
Real-time quantitative PCR (qPCR)
RNA was harvested and extracted as described above for TaqMan lowdensity array analysis and SYBR Green QPCR. TaqMan low-density array (Applied Biosystems, Carlsbad, CA, USA) and qPCR reactions were prepared as previously described. 28 All primers sets, listed in Supplementary Table 4 , used an annealing temperature of 58 1C. PCR reactions were run on an iCycler (Bio-Rad, Hercules, CA, USA). Biological process analysis of gene sets Gene ontology classification of CRGs and oncogenes/tumor suppressors was assigned by mapping Affymetrix probe set IDs to GO biological process categories for each gene via the Affymetrix NetAffx tool (Affymetrix, Santa Clara, CA, USA). NetAffx reported GO biological processes were compared with the NCBI Gene database to check for completeness and consistency.
Chromatin immunoprecipitation and promoter qPCR
Cells were incubated at 37 1C for 15 min in the presence of 1% formaldehyde. This reaction was stopped with the addition of glycine to a final concentration of 0.125 M and incubation at room temperature for 5 min. Cells were then washed 2 Â with ice-cold phosphate-buffered saline, scraped, pelleted and stored at À 80 1C until ready for lysis and sonication. An Acetyl-Histone H3 Immunoprecipitation (ChIP) Assay Kit (Millipore, Billerica, MA, USA) was then used according to the manufacturer's protocol. SYBR Green-based qPCR was run using 1 Â Bio-Rad iQ SYBR Green master mix, 0. Western blotting mp53/Ras cells were grown at 39 1C for 2 days, followed by plating into 2.5 mM VA or NB for 3 days before lysis for western blots. SW480 cells were grown in standard conditions, then plated into 2.5 mM VA or NB for 3 days before western analysis. Cell pellets were lysed for 20 min at 4 1C with rotation in RIPA buffer (50 mM Tris-HCL, pH 7.4, 150 mM NaCL, 1% NP-40, 5 mM EDTA, 0.1% sodium dodecyl sulfate, 0.5% deoxycholic acid, protease inhibitor cocktail tablet). Lysates were clarified by centrifugation at 13 000 g for 10 min at 4 1C and quantitated using Bradford protein assay (Bio-Rad). In all, 25 mg of protein lysate was separated by sodium dodecyl sulfatepolyacrylamide gel electrophoresis and transferred to polyvinylidine fluoride membrane (Millipore). Immunoblots were blocked in 5% non-fat dry milk in phosphate-buffered saline with 0.2% Tween-20 for 1 h at room temperature, probed with antibodies against p53 (FL-393, Santa Cruz, Santa Cruz, CA, USA) for all cell lines, H-Ras (C-20, Santa Cruz) for mp53/Ras cells, Ras (Ab-1, Calbiochem, Billerica, MA, USA) for SW480 cells and tubulin (H-235, Santa Cruz) for all cell lines. Bands were visualized using the ECL þ kit (Amersham, Pittsburgh, PA, USA).
